There’s widespread interest, all the way up to the Oval Office, in driving down prescription drug prices. Where things tend to get stickier, policy wonks say, is in finding a way to do it that doesn’t discourage drug companies from spending big on research.
To try to generate fresh ideas that strike the right balance, the Washington think tank Brookings Institution commissioned a set of three white papers from top scholars. They were released this week.
About the Author Reprints
